SIGN 155 Pharmacological management of migraine from Healthcare Improvement Scotland (HIS)

This SIGN guideline which provides recommendations on the pharmacological management of adults with acute migraine was updated in March 2023. It also covers prophylaxis for patients with episodic or chronic migraine or medication overuse headache. It is intended for use by healthcare professionals in both primary and secondary care as well as for patients.

The key recommendations cover:

• Acute treatment
• Prevention of migraine
• Medication-overuse headache

The latest update from March 2023 includes revised safety advice on use of topiramate, candesartan, flunarazine and CGRP monoclonal antibodies. As well as the recommendation for the use of sodium valproate restricted to patients over the age of 55, and SMC advice on the CGRP monoclonal antibody, eptinezumb, added.

For more information, please visit the SIGN website.